Comparison of percutaneous intradiscal hyalase injection, percutaneous intradiscal ozone injection, and percutaneous laser disc decompression in radiculopathy of patients with herniated lumbar disc

Start Date26 Feb 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

NCT05455697

/ RecruitingPhase 1/2IIT

Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found on B-cells (a type of white blood cell) and some types of cancer cells. Rituximab binds to a protein called CD20, which is also found on B-cells and some cancer cells. These monoclonal antibodies may help the immune system kill cancer cells. Immunotherapy with other monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as CHOP and PolaCHP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TRR in combination with CHOP or PolaCHP may kill more cancer cells.

Start Date26 Jan 2023

Sponsor / Collaborator

University of Washington

NCT05671172

/ RecruitingNot ApplicableIIT

Effect of Adding Two Different Doses of Hyaluronidase to Bupivacaine in Ultrasound-Guided Transversus Abdominis Plane (TAP) Block for Post-cesarean Section Analgesia; A Randomized Controlled Double Blinded Study.

Since TAP block needs to affect several nerves in single tissue plane with a single prick, hyaluronidase is expected to aid greatly in the spread of the LA and help the block. However, there have not been adequate studies to establish the efficacy of adding hyaluronidase in lateral TAP after cesarean section. Hence, the present study was carried out to evaluate the efficacy of hyaluronidase in different concentrations added to bupivacaine in US-guided bilateral lateral TAP block.

Start Date15 Aug 2022

Sponsor / Collaborator

Benha University

100 Clinical Results associated with Hyaluronidase Recombinant Human

100 Translational Medicine associated with Hyaluronidase Recombinant Human

100 Patents (Medical) associated with Hyaluronidase Recombinant Human

133

Literatures (Medical) associated with Hyaluronidase Recombinant Human

01 May 2025·JTO Clinical and Research Reports

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

Article

Author: Young, Fiona ; Majem, Margarita ; Liu, Xiaoyan ; Tosti, Nadia ; Zvirbule, Zanete ; Cappuzzo, Federico ; Korbenfeld, Ernesto ; Szczesna, Aleksandra ; Castro Sanchez, Amparo Yovanna ; Kolb-Sielecki, Jaroslaw ; Bustillos, Alberto ; Isla, Dolores ; Monteiro, Marta Freitas

IntroductionSubcutaneous (SC) atezolizumab, a co-formulation containing atezolizumab and recombinant human hyaluronidase PH20), has been approved for use in more than 50 countries for the same indications as intravenous (IV) atezolizumab. IMscin002 (NCT05171777), a phase 2, randomized, open-label, crossover trial, investigated patient preferences and health care professionals' (HCPs') perceptions of atezolizumab SC versus IV for the treatment of NSCLC; we report the primary results of IMscin002.MethodsPatients with programmed death-ligand 1-positive resected NSCLC who had completed adjuvant chemotherapy without evidence of recurrence, and chemotherapy-naive patients with programmed death-ligand 1-high metastatic NSCLC were randomized 1:1 to arm A (atezolizumab SC then atezolizumab IV) or arm B (atezolizumab IV then atezolizumab SC). After cycle 3, patients switched administration routes. After cycle 6, the patients chose the route of administration for the continuation period. The primary end point was patient preference for SC or IV atezolizumab, and the secondary end points were patient- and HCP-reported outcomes and safety.ResultsA total of 179 patients were included in this study. Most patients (70.7%; n = 87 of 123) preferred SC atezolizumab over IV, with 79.4% (n = 85 of 107) choosing SC atezolizumab during the continuation period. Among the HCPs, 75.2% (n = 76 of 101) indicated that atezolizumab SC was more convenient than IV, and 77.8% (n = 77 of 99) strongly agreed or agreed that it would allow patients to spend less time in care units. No new or unexpected safety findings were identified, and switching between administration routes was well tolerated and managed.ConclusionsMost patients preferred SC atezolizumab over IV. There were no new safety findings, and switching between the administration routes was well tolerated. These results support the preference for SC formulations to reduce the treatment burden.

03 Apr 2025·Journal of Cosmetic and Laser Therapy

Delayed inflammatory nodule from predominantly low-molecular-weight hyaluronic acid filler secondary to COVID-19 infection

Article

Author: Verma, Kritin K. ; Mishra, Vineet ; Mehta, Eshani ; Friedmann, Daniel P.

Delayed inflammatory nodules (DIN) after soft-tissue filler injection may occur after infections, vaccinations, or procedures. We report a DIN from predominantly low-molecular-weight HA (PLMW-HA) filler secondary to COVID-19 infection that was resistant to conservative management, requiring intralesional combination therapy with triamcinolone, 5-fluorouracil, and recombinant human hyaluronidase for resolution.

01 Mar 2025·Journal of Drugs in Dermatology

Effect of Recombinant Human Hyaluronidase on Conventional Hyaluronic Acid Fillers: An In Vitro Analysis

Article

Author: P. Wyles, Saranya ; Handfield, Chelsea ; Hooper, Deirdre

BACKGROUNDHyaluronic acid (HA) fillers offer an advantage in being easily reversible with enzymatic hyaluronidase administration. Yet, there are no clear guidelines regarding the amount of hyaluronidase that should be administered given that commercially available fillers differ in constituent properties.METHODSSix HA fillers were mixed with aliquots of human recombinant hyaluronidase (0 mL, 0.1 mL, 0.2 mL, and 0.3 mL). Filler dilution photography was obtained with the addition of various doses of hyaluronidase. Final filler and hyaluronidase mixture was then visualized on light microscopy at 40X magnification.RESULTSNone of the fillers responded to the direct addition of hyaluronidase alone. Active mixing was required to stimulate the enzymatic effect. Restylane products which have equal concentrations at 20 mg/mL exhibited similar rates of dissolution. In contrast, Juvederm products, which differ in concentration, exhibited variable rates of dissolution. Juvederm Volbella (15 mg/mL) was the most easily dissolvable filler, in contrast, Juvederm Ultra (24 mg/mL) was the least easily dissolvable filler. Microscopically, Juvederm fillers appeared more refined whereas the Restylane fillers appeared more globular following hyaluronidase.CONCLUSIONThis study demonstrates the in vitro response of different HA fillers to hyaluronidase. Each filler exhibited a variable dose effect. HA concentration (mg/mL) was the critical variable in determining the rate of hydrolysis. Therefore, HA concentration may be an important factor when calculating the dose of hyaluronidase needed to reverse HA fillers. J Drugs Dermatol. 2025;24(3):303-306. doi:10.36849/JDD.8428.

109

News (Medical) associated with Hyaluronidase Recombinant Human

28 Apr 2025

·www.prnewswire.com

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. The SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years. "We are delighted that the subcutaneous injection of VYVGART® co-formulated with our ENHANZE drug delivery technology, has been recommended for approval in the European Union. The positive CHMP opinion moves argenx closer to offering patients throughout Europe a groundbreaking new treatment option. We are proud to support argenx achieve their vision of developing innovative, targeted treatments for patients with rare and severe autoimmune diseases," said Dr. Helen Torley, president and chief executive officer of Halozyme. The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the CHMP recommendation, and the ADHERE study and its findings, please view argenx's press release issued on April 28, 2025. The EC is expected to make a decision following CHMP recommendation and the decision will apply to all 27 European Union Member States, and also to Iceland, Norway and Liechtenstein. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding the product development efforts of Halozyme's ENHANZE® partner and the potential approval of an extension of marketing authorization for the subcutaneous formulation referred to in this press release and the timing of such potential approval. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning whether the extension of marketing authorization for the subcutaneous formulation referred to in this press release is delayed or ultimately approved, unexpected results or delays in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalClinical Result

25 Apr 2025

·www.fiercepharma.com

Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal

None AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a positive phase 3 readout. Akeso's bispecific ivonescimab has bagged a phase 3 win when combined with chemotherapy in first-line lung cancer. Fujifilm Diosynth Biotechnologies signed a 10-year manufacturing contract with Regeneron.1. AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancerAstraZeneca and Daiichi Sankyo said a phase 3 trial of their Enhertu has met its primary endpoint of progression-free survival in first-line HER2-positive breast cancer. The antibody-drug conjugate was paired with Roche’s Perjeta and outperformed the standard combination of Perjeta, Herceptin and chemotherapy. The two companies are preparing regulatory filings.2. With new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke'Akeso and Summit Therapeutics’ PD-1xVEGF bispecific ivonescimab has posted another phase 3 trial win. This time, the drug’s combination with chemo beat BeiGene’s PD-1 inhibitor Tevimbra and chemo in Chinese patients with first-line squamous non-small cell lung cancer on progression-free survival. This readout shows that ivonescimab’s previous head-to-head win against Keytruda was “anything but a ‘one hit wonder,’” a Citi analyst said.3. Amid industry's onshoring push, Regeneron taps Fujifilm Diosynth for $3B, 10-year commercial manufacturing team-upRegeneron has penned a 10-year agreement worth more than $3 billion with Fujifilm Diosynth Biotechnologies. The deal will see the Japanese CDMO help manufacture bulk drug product at its Holly Springs, North Carolina, campus for Regeneron’s commercial biologics. The deal will nearly double Regeneron’s domestic manufacturing capacity.4. Stealth biotech bags rights to VelaVigo bispecific in $440M dealShanghai-based VelaVigo Bio has offloaded ex-China rights to a bispecific to Ollin Biosciences for up to $440 million. The target of the asset, VBS-102, was unclear, although Ollin appears to have a focus on ophthalmology. The deal comes six months after VelaVigo sold ex-China rights to a Nectin4xTROP2 bispecific antibody-drug conjugate to Avenzo Therapeutics.5. Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall throughHalozyme has filed a lawsuit against Merck & Co., accusing the New Jersey pharma’s subcutaneous Keytruda infringes 15 of its Mdase family of patents over modified human hyaluronidases. Merck’s SC Keytruda is developed with a hyaluronidase from South Korean company Alteogen.6. Ascletis sees no benefit to high, fast oral GLP-1 dose titration, takes low, slow regimen forwardAscletis posted some baffling phase 1 results from a high dose of its oral GLP-1 prospect ASC30. Thanks to two outliers who lost just 1.8% of their weight after 28 days, the dose’s average weight reduction was even worse than that previously reported for two lower doses. Even after removing those outliers, the high dose performed similarly to a lower dose.7. Tariff hits to generic drugs could 'blow back on everybody' without supply chain resilience, says USP chief8. Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results9. Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA's animal testing shift10. Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals

Phase 3Phase 1Clinical ResultADC

10 Apr 2025

·www.prnewswire.com

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able to self-inject after proper instruction in subcutaneous injection technique. The single dose prefilled subcutaneous injection was developed as part of argenx's exclusive partnership with Halozyme on their ENHANZE® drug delivery technology, which enables rapid, high-volume delivery of biologics "The FDA approval of VYVGART Hytrulo prefilled syringe represents a significant advancement in treatment options for gMG and CIDP patients, enabling self-administration by patients and potentially further reducing the burden of treatment," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We are delighted that argenx continues to expand use of Halozyme's proven ENHANZE technology to support patient independence and convenience." The approval of VYVGART® Hytrulo prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to VYVGART® Hytrulo in a vial. In addition, human factors validation studies demonstrated that participants with gMG or CIDP, or their caregivers, safely and successfully prepared and administered VYVGART® Hytrulo with the prefilled syringe. Previous FDA approval of VYVGART® Hytrulo for patients with gMG and CIDP was based on the global Phase 3 ADAPT, ADAPT-SC and ADHERE trials. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations by enabling self-administration and broadening the treatment options for the indication referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 3

100 Deals associated with Hyaluronidase Recombinant Human

External Link

KEGG	Wiki	ATC	Drug Bank
D06604	-	-	DB06205

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Drug adjuvant	United States	Halozyme Therapeutics, Inc.	02 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypercholesterolemia	Phase 1	Belgium	Halozyme Therapeutics, Inc.	01 Feb 2016
Diabetes Mellitus, Type 2	Discovery	United States	Halozyme Therapeutics, Inc.	01 Aug 2010
Dermatitis, Allergic Contact	Discovery	United States	Halozyme Therapeutics, Inc.	23 Jun 2009
Non-Muscle Invasive Bladder Neoplasms	Discovery	United States	Halozyme Therapeutics, Inc.	30 Mar 2006
Pain	Discovery	United States	Halozyme Therapeutics, Inc.	01 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04606381 (PALOMA, AACR2022) Manual	Phase 1	Advanced Malignant Solid Neoplasm	33	rHuPH20+amivantamab	(xdcgkgupgs) = agytxnortr psmgsagzkf (iuwdzhcbfl )	Positive	15 Jun 2022
NCT00928447 (CTgov)	Phase 2	Dermatitis, Allergic Contact	22	Placebo+rHuPH20	cinhsyxgex(urlhhillhb) = xlkzzuwcyb bauilgkfqm (rjyvdtwpfy, uweftzzvpv - qidadokcfg) View more	-	17 Dec 2021
NCT00318643 (CTgov)	Phase 1/2	Non-Muscle Invasive Bladder Neoplasms	27	Mitomycin C+Chemophase (Cohort 5: MMC Plus Chemophase 800,000 U)	hvcqtubwqi(jbucabsyzu) = vnlgyvwesz gsjutvlxkx (dgvpicffhd, qavwdlnbwg - tzyfnbxqks) View more	-	29 Oct 2021
				Mitomycin C+Chemophase (Cohort 1: MMC Plus Chemophase 20,000 U)	thcljxqiqp(mrqefpsduy) = keblvjfcjw ydartnfxtv (hmfbfsxvzg, uetajtbyyw - blncgzcrnt) View more
NCT01928030 (CTgov)	Phase 1/2	Neoplasms \| Lymphedema	3	rHuPH20+Chemophase	zkzjyyghwr(kuxsersbwj) = uvlclgauiu aaduhyluwt (pqwyxboyyr, gprnfrtrxg - bspkbgaoaz) View more	-	07 Feb 2017
NCT01194245 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	135	insulin lispro+recombinant human hyaluronidase PH20 (Analog-PH20)	phjnkjufei(ukgqxikfds) = pyierljjzf xzwdmqsthv (kprfqmnfeq, yihsfmekde - aggrhgtyrn) View more	-	19 Aug 2014
				Insulin Lispro (Insulin Lispro)	phjnkjufei(ukgqxikfds) = wcbhpdlfwr xzwdmqsthv (kprfqmnfeq, yltugyaytc - rtinersqzz) View more
NCT00862849 (CTgov)	Phase 1	Diabetes Mellitus	22	rHuPH20+Insulin Lispro (Insulin Lispro + rHuPH20)	usxbmqeazf(sdcfyixoou) = zaofvnsdcu wdbfetfqhn (fynmbxzvnq, ywnisnnrru - qziovczfjf) View more	-	11 Jul 2014
				Insulin+rHuPH20 (Regular Human Insulin + rHuPH20)	usxbmqeazf(sdcfyixoou) = mwcvjsptop wdbfetfqhn (fynmbxzvnq, hjghgmqrjq - ineewwvbpz) View more
NCT01116102 (INFUSE-AT1A, CTgov)	Phase 4	Dehydration	20	Lactated Ringer's solution (24 ga Catheter, Dose Flush, Single-step Rate Scheme)	irixekudyn(zbscdhaeca) = xygwalsppl evxxbjjxbt (qhrsiicxyg, byclwcgnld - ktflpvfaxr) View more	-	18 Oct 2011
				Lactated Ringer's solution (24 ga Catheter, No Dose Flush, Single-step Rate Scheme)	irixekudyn(zbscdhaeca) = ifhxfjgbcs evxxbjjxbt (qhrsiicxyg, tkhvsbzzda - fghhvxktdq) View more
NCT00807885 (INFUSE-AT, CTgov)	Phase 4	Dehydration	100	hylenex+Lactated Ringer solution (Tegaderm-secured 24 ga Teflon Catheter)	grqtrvvzhu(lopixzzmeb) = tkavgmhqmx dnjfdirsal (zppphkdeio, hhpktmuuah - cjfaoopjwt) View more	-	18 Oct 2011
				hylenex+Lactated Ringer solution (Tape-secured 24 ga Teflon Catheter)	grqtrvvzhu(lopixzzmeb) = knyhbuujhr dnjfdirsal (zppphkdeio, zhhzluhllj - kpnvwfbeun) View more
NCT00656370 (INFUSE-NSLR, CTgov)	Phase 4	-	15	Recombinant human hyaluronidase (NS Infusion Group)	(xwfmiokiqf) = xbemdvyttx vdlblghqvp (yftdufgndd, kynmaavkoa - xfovaqshem) View more	-	14 May 2010
				Recombinant human hyaluronidase (LR Infusion Group)	(xwfmiokiqf) = zgvmkprplp vdlblghqvp (yftdufgndd, oivztpndgq - tfwygcqcur) View more
NCT00477152 (INFUSE, Pubmed \| Pediatrics)	Phase 4	-	51	Recombinant human hyaluronidase (rHuPH20)	acoeghohan(uarwlbeyen) = 1 serious adverse event occurred (cellulitis at infusion site) hopsybjjqj (lwajtyjlum ) View more	-	01 Nov 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis